PD-1 Pathway Inhibition: Potential Trigger of Anti-GBM Glomerulonephritis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0751; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 52-year-old female with metastatic melanoma was initially treated with Pembrolizumab before transitioning to Nivolumab due to recurrence...The patient was started on dialysis, daily plasma exchange, IV pulse steroids, and cyclophosphamide...Interstitial nephritis is a known adverse effect of immune checkpoint inhibitors, but reports of glomerulonephritis, especially anti-GBM disease, remain extremely rare, with only a few cases reported 1 . Current National Comprehensive Cancer Network guidelines for immune checkpoint inhibitor–related renal toxicity recommend anti-GBM antibody testing when there is concern for ICI-induced vasculitis or glomerulonephritis 2 ."
Glioblastoma • Glomerulonephritis • Immunology • Lupus Nephritis • Melanoma • Nephrology • Pneumonia • Solid Tumor • Vasculitis
|
|
Rachel L. Fine; Mohamed Ahmed Younis; Tyler Sims; Sadiq Ahmed
|